Veracyte Inc VCYT:NASDAQ

Last Price$26.02Cboe Real-Time Last Sale as of 12:18PM ET 9/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.43(1.68%)
Bid (Size)$25.98 (100)
Ask (Size)$26.03 (1)
Day Low / High$25.38 - 26.31
Volume191.7 K
  • Latest Stories
  • Commentary and Analysis
Insider Trends: Veracyte Insider Extends 90-Day Selling Trend
5:47PM ET 9/12/2019 MT Newswires

Bonnie H Anderson, Director and Chairman & CEO, sold 8,000 shares of Veracyte (VCYT) on Sep 10, 2019, for $196,114. Subsequent to the Form 4 filing with...

::C22310FF-6260-40DE-80A4-4FE49D389E51}} Time 9/5/2019 5:24:24 PM File did not print ref HEADLINEACTION.16 FTMUM 16 CODE FMS
5:25PM ET 9/05/2019 MT Newswires

File did not print ref INSIDERACTIVITY.16 FTMUM 16 CODE FMS Dr Kennedy, following the transactions disclosed in the Form 4 SEC filing, owns 47,449 company...

Insider Trends: Veracyte Insider Sale Scales Back 90-Days of Buys
4:34PM ET 8/29/2019 MT Newswires

On Aug 27, 2019, Director, Evan Jones, executed a sale of 10,000 shares in Veracyte (VCYT) for $261,051. Jones has control over 204,653 company shares of...

Insider Trends: Veracyte Sees 90 Days of Insider Buying Trend Slowing with Share Sale
4:26PM ET 8/12/2019 MT Newswires

Evan Jones, Director, sold 15,000 shares of Veracyte (VCYT) on Aug 09, 2019, for $395,681. Following the Form 4 filing with the SEC, Jones controls a...

Insider Trends: Insider at Veracyte Converts Options in Mist of 90-Day Buying Trend
4:20PM ET 8/05/2019 MT Newswires

Fred E Cohen, Director, exercised options for 40,000 shares in Veracyte (VCYT) for $368,200 on Aug 02, 2019. Cohen, following the transactions detailed in...

--Analyst Actions: Janney Raises Price Target on Veracyte to $33 From $27, Maintains Buy Rating
8:49AM ET 7/31/2019 MT Newswires

Price: 29.61, Change: 0.00, Percent Change: 0.00 ...

Veracyte Posts Narrower Q2 Loss vs Estimate, Revenue Narrowly Beats Forecast; Lifts FY2019 Revenue Outlook
6:39AM ET 7/31/2019 MT Newswires

Veracyte (VCYT) reported late Tuesday Q2 net loss of $0.05 per share compared to a net loss of $0.18 per share in the year-ago period. Wall Street analysts...

Analyst Actions: Needham Starts Veracyte at Buy, Price Target is $33
9:09AM ET 7/02/2019 MT Newswires

Veracyte (VCYT) has an average rating among analysts of buy, with an average price target of $18 Price: 28.75, Change: +0.24, Percent Change: +0.84 ...

Veracyte COO To Retire
4:09AM ET 7/01/2019 MT Newswires

Veracyte (VCYT) said in a Friday regulatory filing that Christopher Hall intends to retire as COO, effective July 1. Keith Kennedy, the company's current...

Veracyte Says Cancer Cytopathology Details Co.'s Role in Reducing 'Unnecessary' Surgeries in Thyroid Cancer Diagnosis
2:56PM ET 6/17/2019 MT Newswires

Veracyte (VCYT) said Monday a review article in Cancer Cytopathology, a journal of the American Cancer Society, describes how the technology behind...